Eye-On-a-Chip Device

CEVR
Overview

Eye-On-a-Chip Device is the next generation in vitro testing platform designed for accurately testing eye products, such as drugs. It provides more reliable preclinical data and is specifically tailored for researchers and pharmaceutical companies.

  • Eye-On-a-Chip Device 0
  • Eye-On-a-Chip Device 1
Problem addressed

Traditional in vitro testing platforms have poor reliability and weak correlation to clinical outcomes, leading to high failure rates in new drug development, especially in later clinical trials. CEVR has developed an" Eye-On-a-Chip Device" that uses microfluidic and 3D organoid technologies to simulate the eye's microenvironment, significantly enhancing prediction accuracy, reducing reliance on animal testing, accelerating drug development, and lowering costs and time.

Innovation
  • Dynamic Microenvironment Simulation: Utilizing microfluidic technology to create a dynamic environment that simulates the microenvironment of eye cells, such as the process of tears flowing over the cornea, to better mimic physiological conditions.
  • 3D Organoid Integration: By combining microfluidic technology with 3D organoid regenerative medicine techniques, we can more accurately replicate human eye tissue, enhancing the ability to predict drug responses.
  • Reduced Dependence on Animal Testing: The product significantly decreases reliance on animal experiments in the drug development process, promotes progress in animal ethics, and accelerates the drug development timeline.
Key impact
  • The product accurately simulates the eye's microenvironment, enhancing the reliability of preclinical results. It significantly increases the success rate of drug development, accelerates the drug development process, and reduces R&D costs and time.
  • The product reduces the reliance on animal models in preclinical research, which aligns with current ethical trends.
  • As the world's only company focused on eye cell/organoid chips, we are rapidly entering the mainland market and expanding our customer base through collaboration with a Contract Research Organization (CRO) that holds a significant market share in China.
Award
  • Gold Medal at the 9th China (Shanghai) International Invention & Innovation Expo
  • Gold Medal at the 2025 International Exhibition of Inventions in Geneva
  • Gold Medal at the 2024 Asia Exhibition of Innovations and Inventions in Hong Kong
  • CAI Award from the China Association of Inventions at 2024
  • Top Performers in PolyU Microfund 2024 Cohort

Patent

  • The US Provisional Utility Patent Application no is 63/743,219

The InnoHK Centre for Eye and Vision Research (CEVR) was established in 2020 as a research collaboration between The Hong Kong Polytechnic University (PolyU) and the University of Waterloo (UWaterloo) in Canada. It is located at the Hong Kong Science Park, Shatin, Hong Kong. It is one of the research laboratories under the "InnoHK Research Clusters" initiative of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government. CEVR is committed to developing technologies that prevent, detect, treat, and mitigate vision loss, driving ground-breaking research across three key areas: Preserving and Restoring Healthy Vision, Next-Generation Therapeutics, and Advanced Optometry Technologies. For further information, please visit www.cevr.hk.

Enquiry
Related Innovations